Shanghai, China, February 07, 2024 — MicroPort® CRM’s latest generation transvenous MR-conditional safe implantable pacemaker system has obtained approval in China.
The ENO™ pacemaker family, including ENO™, TEO™, and OTO™, features a compact volume of only 8cc and a projected longevity of up to 12 years. Comprising the ENO™ pacemaker and Vega™ pacing leads available in 3 lengths for clinical flexibility, this system is compatible with 1.5T/3T full-body MRI scans.
Featuring an AutoMRI™ mode, the ENO™ increases patients’ safety and quality of life when undergoing an MRI examination. The pacemaker automatically switches to activate the MRI mode upon entering the MRI field and reverts to its initial settings following the exam. This technology allows patients to have repeated MRI scans within 10 days without further intervention, significantly improving workflow for both patients and medical staff.
As part of the “Clinical Investigation of ENO/TEO/OTO Pacing System (CAPRI) study conducted in 29 clinical centers worldwide, the ENO™ system’s safety and efficacy under MRI conditions was demonstrated . The research findings were published in the authoritative journal “European Radiology “ in 2023. 1
About MicroPort® CRM
MicroPort®
CRM is a pioneering company in the field of Cardiac Rhythm Management (CRM) with global headquarters in Clamart, near Paris, France and an associated company of MicroPort® (MicroPort Scientific Corporation; HKEX: 00853). Through its long-standing expertise in CRM, MicroPort® CRM develops, manufactures and commercializes cardiac pacemakers, implantable cardiac defibrillators, cardiac resynchronization systems and ECG diagnostic solutions for the management of cardiac rhythm disorders and heart failure, globally. These state-of-the-art products are manufactured in Clamart, France, Saluggia, Italy, and in Santo Domingo, Dominican Republic. MicroPort® CRM also distributes MicroPort® solutions in Interventional Cardiology and Electrophysiology in Europe.
More information is available at www.microport.com.
Reference:
1：Dacher JN, Langguth P, Adam D, Winkler WB, Martí-Almor J, Prenner G, et al. Safety and performance of MR-conditional pacing systems with automated MRI mode at 1.5 and 3 Tesla. Eur Radiol 2023;33(10):6948-58.